2014 Fiscal Year Final Research Report
Development of dermatitis therapeutic drug with thioredoxin and thioredoxin inducer
| Project/Area Number |
24591652
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 皮膚炎症 / アトピー性皮膚炎 / チオレドキシン / 接触皮膚炎 / 外用療法 |
|---|
| Outline of Final Research Achievements |
The central medical therapy of eczema including atopic dermatitis has been both topical steroid and topical immunosuppressant for many years. In this study, we focused on thioredoxin (TRX), which has a crucial role in redox regulation. We demonstrated that topically applied recombinant human TRX (rhTRX) ameliorated a murine irritant contact dermatitis by regulating the epithelial production of pro-Inflammatory cytokines. We made an external agent containing rhTRX, which did not show allergic or irritant reaction in healthy volunteers. We have completed the double-blinded, randomized, placebo-controlled study in 20 patients with atopic dermatitis. Any side effects and harmful phenomenon did not occur in this study. This data are being analyzed.
|
| Free Research Field |
皮膚アレルギー
|
